Biomarker based depression test

Majority of depresion cases are not at all or very late discovered

The Project

More than 300 million people are affected by depression with more than 700,000 suicides annually. Nevertheless, too many people do not receive therapy, since more than 50% of all depression cases are not recognized and even if in therapy remission is low, due to lack of an personalized approach.

Our part of the solution is the development of an objective biological urine test for home use as a low-threshold offer for early detection of depression. Based on this, we would like to develop a test for the correct therapy selection for physicians.

Fraunhofer SCAI conducts extensive in-silico research to identify and validate biomarkers. Furthermore, identifying biological homogenous subtypes tremendously increases validity.

Due to our impact on reduction of suicides we received an additional funding from the selective SDG track.

The Team

Location: Frankfurt and Sankt Augustin

Members: **Moritz Gölkel (Founder),** Dr. Marc Jacobs (Fraunhofer SCAI, Project Lead), Prof. Dr. Martin Hofman-Apitius (Fraunhofer SCAI, senior adviser)

AHEAD Infos

Batch: 2022 May   **Phase:** 1   **Track:** Spin-Off / Licensing

The Business Model

Unique Selling Proposition:	Scientifically validated biomarker test to enable early and low threshold detection
Unfair Advantage:	First to market with an objective (not based on questionnaire), biological test and therefore reduces stigmatization of depression
Revenue Model:	Product sales

Venture Readiness Level

VRL	Ideation	Incubation	Traction	Growth

Technology Readiness Level

TRL	1	2	3	4	5	6	7	8	9

The Side Facts

Customer Focus:	B2C (initially), B2B (physicians, pharma)
Searching For:	1. Co-Founder, 2. medical research partner, 3. expert interview partner
Industry Tags:	Health care
Technology Tags:	medical devices, personalized treatment, preventive healthcare